Compare SACH & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | ICCC |
|---|---|---|
| Founded | 2010 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 55.5M |
| IPO Year | 2017 | 1987 |
| Metric | SACH | ICCC |
|---|---|---|
| Price | $1.06 | $6.27 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 141.8K | 25.5K |
| Earning Date | 11-05-2025 | 02-25-2026 |
| Dividend Yield | ★ 18.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $3,906,000.00 | ★ $27,769,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.73 | N/A |
| P/E Ratio | ★ N/A | $24.27 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $0.80 | $4.28 |
| 52 Week High | $1.35 | $7.60 |
| Indicator | SACH | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 52.97 |
| Support Level | $1.03 | $6.15 |
| Resistance Level | $1.07 | $6.92 |
| Average True Range (ATR) | 0.02 | 0.33 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 57.14 | 31.82 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.